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ABSTRACT 
 
OBJECTIVE: The objective of this selective evidence based medicine (EBM) review is to 
determine whether or not “Is electroacupuncture effective in improving quality of life for women 
with urinary incontinence?” 
 
STUDY DESIGN:  A systematic review of 3 peer-reviewed studies published between the years 
of 2014 and 2017. 
 
DATA SOURCES: Two randomized placebo-controlled studies and one comparative study 
evaluating if electroacupuncture (EA) and/or the use of tolterodine improves the quality of life 
and therapeutic effects of those with urinary incontinence (UI).  Sources were selected from 
PubMed and Cochrane Library based off of their relevance to the clinical question and the 
outcomes being patient oriented. 
 
OUTCOME(S) MEASURED: The outcomes measured depended on the study, although all 
were patient oriented.  Quality of life was measured through The International Consultation on 
Incontinence Questionnaire-Short Form (ICIQ-SF), whereas evaluation of therapeutic effects and 
UI severity were self-reported. 
 
RESULTS:  The study conducted by Lui Z, Liu Y, Xu H, et al.,1 showed statistically significant 
improvement of quality of life (95% CI, p<0.001), as well as reduction of UI symptoms depicted 
by self-reported SUI severity (p=0.03), and evaluation of therapeutic effects (p<0.001).  The 
study conducted by Xu H, Liu B, Wu J, et al.,2 revealed statistically significant results as well 
with the self-evaluation of therapeutic effect having a p-value of <0.001, and quality of life 
having a p-value=0.001.  Lastly, the study conducted by Jin C, Zhou X, Pang R3 had a 
statistically significant result for quality of life (p<0.001), indicating that both groups responded 
to their respective treatment.  At the end of week 8, there was no difference of patient-reported 
improvement between groups, indicating that tolterodine didn’t provide additional benefit. 
 
CONCLUSIONS:  The evidence presented in this review reveals that there is satisfactory data 
to conclude that EA improves the quality of life of women who have UI.  This review also 
indicates that tolterodine doesn’t provide additional benefit of UI symptoms.  Further research is 
warranted to evaluate symptom improvement from EA compared to traditional pelvic floor 
training exercises. 
 
KEY WORDS: Electroacupuncture and urinary incontinence 
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INTRODUCTION 
Stress Urinary Incontinence (SUI) can be defined as an involuntary loss of urine on 
physical exertion, sneezing or coughing.1,2  Mixed Urinary Incontinence (MUI) can be defined as 
involuntary loss of urine associated with urgency and also with exertion, effort, sneezing, or 
coughing.3 
Urinary incontinence (UI) is a common disorder and is encountered in almost every 
medical specialty.  Around 34.4% of American women experience MUI but in certain 
populations, SUI has a prevalence of around 49%.1,3  UI causes “psychological burden, affects 
relationships, lowers physical productivity, and decreases quality of life in women,” making it a 
worthwhile topic to research and evaluate.1  This disorder is also financially taxing and requires 
multiple office visits.  In 2007, an estimated cost of $65.9 billion was used in the treatment of 
overactive bladder with urge urinary incontinence (UUI).4  In 2009, an estimated 8.1 million 
visits were made by US women in regards to overactive bladder treatment with anticholinergic 
medications.5  
It is known that “continence depends on having intact micturition physiology as well as 
the functional ability to toilet oneself.”6  UI can be classified as stress, urge, mixed, or overflow.  
SUI is due to urethral hypermobility, and intrinsic sphincteric deficiency, whereas UUI is due to 
detrusor overactivity.6  MUI has a combination of stress and urge pathophysiology.  As of now, 
quick and effective treatments of UI are unknown.  Conservative therapies that have been used as 
treatment include pelvic floor muscle training, bladder training, incontinence pads, weight loss, 
dietary changes, and smoking cessation.7  If patients are refractory to conservative therapies, 
other alternatives include pessaries, topical vaginal estrogen, anticholinergic medications, or 
surgery.7 
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Pelvic floor muscle training, also known as Kegel exercises, is a free and simple option 
as a first line conservative therapy for UI.  Due to pelvic floor muscle training taking up to 3 
months before benefit is observed, there is a need for a quicker, easier, and more effective 
treatment for UI.2  Electroacupuncture (EA), a specialized therapeutic method in which a small 
electrical charge is applied to needles that are inserted into specific points,”8 may be used as the 
alternative to relieve the symptoms of UI in a timelier manner. 
OBJECTIVE 
The objective of this selective evidence based medicine (EBM) review is to determine 
whether or not “Is electroacupuncture effective in improving quality of life for women with 
urinary incontinence?” 
METHODS 
This paper evaluates two randomized, placebo-controlled studies and one comparative 
study assessing EA, and its benefit on UI.  One of articles also evaluates the use of tolterodine, 
“an antimuscarinic agent that has been shown to inhibit detrusor overactivity via binding to 
muscarinic receptors in the detrusor smooth muscle,”3 in combination with EA.  The inclusion 
criteria and exclusion criteria used for selection are found in Table 1. 
The keywords “electroacupuncture” and “urinary incontinence” were used and sources 
were selected based on their relevance to the clinical question and if they included patient-
oriented outcomes.  The articles were written in English and published in peer-reviewed journals.  
The articles were found from PubMed and Cochrane Library with inclusion criteria of being 
published after 2008.  The statistics reported included p-values, Confidence Interval (CI), 
Relative Benefit Increase (RBI), Absolute Benefit Increase (ABI), and Number Needed to Treat 
(NNT). 
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Table 1 - Demographics of included studies1,2,3 
Study Type # 
Pts 
Age (yrs) Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Liu1 
(2017) 
Randomized, 
Participant-
blinded, sham 
EA-
controlled 
Study 
504 EA group: 
54.5 + 8.3 
 
Control 
group: 
56.2 + 8.4 
40-75 y/o, had 
SUI, and had 
incontinence 
pad weight 
gain >1g in 
the 1-hr pad 
test 
Urinary frequency 
or urgency, pad wt 
gain <1g in 1-hr 
pad test, UTI, hx 
of pelvic or UI 
surgery, residual 
urine volume of 
>30 mL or 
maximal flow 
rates <20mL/s, not 
40-75 y/o, POP 
>stage 2 
18 18 sessions 
(over 6 weeks) 
of EA 
involving the 
lumbosacral 
region or 
sham EA with 
no skin 
penetration on 
sham 
acupoints 
Xu2 
(2016) 
Randomized, 
Placebo-
controlled 
Study 
80 EA group: 
59.05 + 
7.91 
 
Sham EA 
group: 
57.97 + 
8.42 
40-75 y/o, had 
SUI, visible 
involuntary 
leakage from 
urethra 
synchronous 
w/ increased 
abdominal 
pressure, and 
had an 
incontinence 
pad weight 
gain >1g in 1-
hr pad test 
Other types of UI, 
UTI, hx of pelvic 
or UI surgery, 
residual urine 
volume of >30 mL 
or maximal flow 
rates <20mL/s, 
POP >Stage 2, 
specialized tx for 
SUI, meds 
affecting bladder 
fx, pregnant, 
breastfeeding 
0 EA in 
acupoints of 
bilateral  
BL33 and 
BL35 or sham 
EA 20mm 
lateral to 
acupoints 
BL33 and 
BL35 with 
blunt needle 
tips piercing 
adhesive pads, 
not piercing 
skin surface 
Jin3 
(2014) 
Comparative 
Study 
71 EA group: 
57 + 8 
 
Combo 
Therapy 
group: 
56 + 9 
Female, had 
MUI for >1 yr, 
recorded >1 
UI episode per 
24 hrs in 
bladder diary, 
and >2g of 
urine loss 
based on a 24-
hr pad test 
UTI, bladder 
obstruction, 
closed-angle 
glaucoma, IC, 
POP >Stage 2, 
previous UI 
surgery or post-
void residual 
volume more than 
100mL. 
0 EA at 
acupoints 
BL32, BL35, 
SP6, and 
ST36, 3x/wk 
for 8 weeks or 
same as first 
group plus 
tolterodine 
2mg PO BID 
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OUTCOMES MEASURED 
 The studies used were all patient-oriented.  Jin C, Zhou X, Pang R3 measured only quality 
of life whereas Xu H, Liu B, Wu J, et al.2 assessed quality of life and the evaluation of 
therapeutic effects.  Lui Z, Liu Y, Xu H, et al.1 measured SUI severity, quality of life and the 
evaluation of therapeutic effects. 
RESULTS 
 The study conducted by Lui Z, Liu Y, Xu H, et al., was a randomized, participant-
blinded, sham EA-controlled clinical study that was conducted at 12 hospitals in China.1  In this 
study, 987 women were screened and 504 women were randomized into two groups via a central 
randomization system.1  Participants were placed into the experimental group which received EA 
(n=252) or the control group which received sham EA (n=252).1  Of the 504 participants to start 
the trial, 486 women completed the 6-week treatment, although all 504 women’s data were used 
in the primary analysis.1  Inclusion criteria for this trial included women who were 40-75 years 
old, had SUI, and an incontinence pad weight gain >1g in the 1-hr pad test1; exclusion criteria 
can be found in Table 1.  The experimental group received EA at acupoints BL 33, and BL 35, 3 
times per week for 6 consecutive weeks, for a total of 18 sessions.1  The control group received 
sham EA using a blunt-tipped placebo needle that did not penetrate the skin.1   
The outcomes in this study included quality of life, SUI severity, and evaluation of 
therapeutic effects.  The p-values were calculated using the Wilcoxon rank-sum test.  The 
International Consultation on Incontinence Questionnaire-Short Form, assessed the influence of 
UI on quality of life during the previous 4 weeks.1  The results of this questionnaire proved that 
the EA group had a greater decrease from baseline over the sham EA group with between-group 
differences of 1.5 points (95% CI, p<0.001).1  The SUI severity was rated by participants in a 72-
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hour bladder diary at baseline and at week 6 as either none, mild, medium, or severe (Table 2).  
Table 2 displays that almost the equivalent amount of Sham EA Group participants rated their 
SUI severity the same at the end of week 6 as it was at baseline.  This is in contrast to the EA 
Group, where there is a curtail in SUI severity based on the number of participants that classified 
severity at week 6 less than what it was originally at baseline.  By week 6, 85.4% of participants 
reported at least medium help from EA.1  The p-value at the end of week 6 was 0.03, indicating 
that the results are statistically significant and those who received EA had higher improvement 
than the sham EA group.1 
Table 2: Subjectively-based SUI severity1 
 Baseline Week 6 
Severity of SUI EA Group Sham EA Group EA Group Sham EA Group 
None 7 3 13 6 
Mild 116 127 138 121 
Medium 103 104 88 102 
Severe 26 17 7 17 
The participant self-evaluation of therapeutic effect data was converted to dichotomous 
data and can be found in Table 3.  These results are statistically significant, with a p-value of 
<0.001, indicating that EA did improve patient’s symptoms of UI more than the Sham EA.1 
Table 3: Treatment Effects 
Study CER EER RBI ABI NNT P-value 
Lui1 (2017) 70% 99% 41% 0.290 4 <0.001 
 
The study conducted by Xu H, Liu B, Wu J, et al. was a randomized, placebo-controlled 
study conducted in Guang’anmen hospital in Beijing, China.2  In this study, 181 women were 
assessed for eligibility and 80 were randomized into the study using a central randomization 
system.2  The experimental group (n=40) received EA at BL 33 and BL 35, whereas the control 
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group (n=40) received sham EA with blunt-tipped needles 20mm lateral to acupoints BL 33 and 
BL 35.2  Both groups were treated with 3 sessions per week on alternate days for a total of 6 
weeks.2  Inclusion criteria for this study included women who were 40-75 years old, had SUI, 
visible involuntary leakage from urethra synchronous with increased abdominal pressure, and 
had an incontinence pad weight gain >1g in the 1-hr pad test2; exclusion criteria can be found in 
Table 1.   
The outcomes in this study included patient-reported evaluation of therapeutic effects and 
quality of life.  The patient self-evaluation of therapeutic effect at week 6 was statistically 
significant, with a p-value of <0.001 when compared between groups.2  This data was converted 
to dichotomous data and can be found in Table 4.  Quality of life was measured with the 
International Consultation on Incontinence Questionnaire-Short Form.2  At week 6, the median 
change from baseline in the EA group was 1.75 points in the questionnaire, whereas the median 
change from baseline for the sham EA group was 0 points in the questionnaire.2  These results are 
considered significant with the p-value between groups of 0.001.2 
Table 4: Treatment Effects 
Study CER EER RBI ABI NNT P-value 
Xu2 (2016) 62.50% 100% 60% 0.375 3 <0.001 
 
 The study conducted by Jin C, Zhou X, Pang R was a comparative study that included 71 
women, recruited from Guang An Men hospital and hospital of Acupuncture and Moxibustion in 
China.3  The first group (n=34) received only EA 3 times a week for 8 weeks, whereas the 
second group (n=37) received EA 3 times a week for 8 weeks in addition to tolterodine 2 mg 
twice a day orally.2  The EA acupoints used were BL 32, BL 35, SP 6, and ST 36.2  Inclusion 
criteria include women who have had MUI for >1 yr, recorded >1 UI episode per 24 hrs in 
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bladder diary, and >2g of urine loss based on a 24-hr pad test2; exclusion criteria can be found in 
Table 1.   
The outcome in this study included patient quality of life which was measured by the 
International Consultation on Incontinence Questionnaire (ICIQ), as seen in Table 5.3  The 
results are statistically significant, p-value <0.001, indicating that both groups responded well to 
their respective treatments.3  Although both groups showed improvement in UI symptoms, there 
is no difference of patient-reported improvement between groups from baseline to week 8.3  This 
indicates that the use of tolterodine didn’t provide additional benefit in improving symptoms.3 
Table 5: ICIQ Score at Baseline and Post-Treatment3 
 Baseline Post-Treatment P-Value 
 EA CT EA CT  
How much does leaking urine interfere 
with your everyday life? (Score 0-10) 
8 8 4 4 <0.001 
Abbreviations: EA, Electroacupuncture; CT, Combination Therapy 
 
SAFETY AND TOLERABILITY  
 
Acupuncture is a relatively well tolerated and a safe treatment method for many 
conditions when performed by skilled providers.2  The articles used had few adverse events 
observed during their trials.  The study conducted by Lui Z, Liu Y, Xu H, et al. reported that 
there were four cases of subcutaneous hematomas, three cases of fatigue, one case of sharp pain, 
and one case of palpitations.1  The study conducted by Xu H, Liu B, Wu J, et al. reported there 
were two cases of hematomas at the needling site, three cases of persistent pain after EA, and 
one case of fatigue.2  The study conducted by Jin C, Zhou X, Pang R did not report any adverse 
events. 
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DISCUSSION 
 UI is a burden that many women have to face on a daily basis and although there are 
many non-invasive and conservative treatments available, quicker treatment options are desired.  
Based on the previously discussed successful results, as well as the few adverse outcomes from 
treatment, EA seems to be a strong and expeditious option for treating UI. 
 It is suggested that EA improves SUI because the pelvic floor electric stimulation may 
increase the maximum urethral closure pressure, as well as stimulate the pudendal nerve 
therefore strengthening the pelvic floor muslces.1  Xu H, Liu B, Wu J, et al. concurs that 
neuromodulation of the bladder is the possible mechanism as to why EA works for UI.  The 
authors further discuss that in order to achieve the desired effect from EA, the proper acupoints 
must be chosen based on what anatomical parts of the body need to be stimulated.  In this 
particular case for UI, it is imperative to target the bladder, hence why all three trials used 
acupoint BL 33 and BL 35.  BL33 is located on the posterior branch of the S3 sacral nerve, and 
BL 35 is located on the pudendal nerve.2 
 In order to further improve MUI symptoms, treatment must also target the cause of 
detrusor overactivity.  The antimuscarinic medication tolterodine, has been shown to inhibit 
detrusor muscle activity, and has been proven to increase bladder capacity in rats.3  Although 
there was not a significant difference of UI symptom improvement when comparing EA vs 
combined therapy in this trial, the use of tolterodine has been proven to be a viable option for 
treatment in particular patient populations.  This medication, listed on the Beers Criteria, may 
potentially be inappropriate to prescribe to the geriatric population due to the fact that it has 
anticholinergic properties.9 
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LIMITATIONS 
 
The study conducted by Lui Z, Liu Y, Xu H, et al. had multiple limitations reported in 
their study including the following: “the participant blinding assessment was only performed in 2 
of the 12 centers; the use of fixed block randomization could not prevent bias from the prediction 
of treatment allocation in participants; there was no adjustment made for multiple comparisons 
for secondary outcomes; the 18 sessions of EA treatment over 6 weeks may be burdensome; and 
the EA procedures in the study can be technically challenging.”1 
The limitations of the study conducted by Xu H, Liu B, Wu J, et al. includes lack of 
validation on the blinding effect of the Sham EA group, which may overstate the treatment effect 
of the EA group, as well as the trial’s small sample size.2 
Limitations of the study conducted by Jin C, Zhou X, Pang R includes lack of a parallel 
placebo-control group, and nonblind design.3  This study also only did a “post hoc power 
analysis, but not a prestudy power analysis.”3 
CONCLUSION 
 Based on the two RCTs and the one comparative study, there is satisfactory data to 
conclude that EA improves the quality of life of women who have UI.  Future studies should 
compare EA to traditional pelvic floor training exercises to determine if there is comparable 
benefit, and if so, what length of therapy is needed to see the similar benefit. 
One flaw noted was within the first article.  There were eight participants that never 
received EA therapy, yet their data was used in the primary analysis.1  A second flaw noted was 
that the same ethnicity was used in all three trials. It would be beneficial to diversify the subjects 
studied, as this condition occurs across multiple ethnicities.  
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